Glutamate and its receptors are involved in the pathophysiology of mood disorders and have recently emerged as potential targets for the pharmacotherapy of depression. In rats, we investigated plasticity changes of the glutamatergic system evoked by electroconvulsive shock (ECS), which represents the most effective therapy for patients who are refractory to antidepressants. Chronic ECS produced a marked increase in the phosphorylation of the regulatory NMDA receptor subunit NR2B (Ser1303) and the AMPA receptor subunit GluR-A (Ser831) in the hippocampus, with no effects on the obligatory subunit NR1. No effects were found on total receptor subunit expression levels. We suggest that, at least in part, ECS exerts its clinical activity through ...
Background: Several reports have shown that the glutamatergic system is involved in both the pathoge...
During early stages of postnatal development, glutamate receptors of NMDA and AMPA type, undergo int...
WOS: 000330362600012PubMed: 23807397Objectives Glycogen synthase kinase 3 beta (GSK-3 beta) is recen...
Glutamate and its receptors are involved in the pathophysiology of mood disorders and have recently ...
Electroconvulsive therapy (ECT) is an efficient and relatively fast acting treatment for depression....
The neural basis underlying the cognitive side effects of ECT is unknown. Recent studies suggest tha...
Converging clinical and preclinical evidence has shown that dysfunction of the glutamate system is a...
Glutamatergic abnormalities have recently been implicated in the pathophysiology of depression, and ...
We investigated the effect of electroconvulsive shock (ECS), administered five times over 10 days, o...
Recent compelling evidence has suggested that the glutamate system is a primary mediator of psychiat...
Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depr...
Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depr...
Clinical studies on patients with stress-related neuropsychiatric disorders reported functional and ...
The presence of high concentrations of glutamate in the extracellular fluid following brain trauma o...
Growing evidence suggests a pivotal role for glutamatergic neurotransmission in the pathophysiology ...
Background: Several reports have shown that the glutamatergic system is involved in both the pathoge...
During early stages of postnatal development, glutamate receptors of NMDA and AMPA type, undergo int...
WOS: 000330362600012PubMed: 23807397Objectives Glycogen synthase kinase 3 beta (GSK-3 beta) is recen...
Glutamate and its receptors are involved in the pathophysiology of mood disorders and have recently ...
Electroconvulsive therapy (ECT) is an efficient and relatively fast acting treatment for depression....
The neural basis underlying the cognitive side effects of ECT is unknown. Recent studies suggest tha...
Converging clinical and preclinical evidence has shown that dysfunction of the glutamate system is a...
Glutamatergic abnormalities have recently been implicated in the pathophysiology of depression, and ...
We investigated the effect of electroconvulsive shock (ECS), administered five times over 10 days, o...
Recent compelling evidence has suggested that the glutamate system is a primary mediator of psychiat...
Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depr...
Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depr...
Clinical studies on patients with stress-related neuropsychiatric disorders reported functional and ...
The presence of high concentrations of glutamate in the extracellular fluid following brain trauma o...
Growing evidence suggests a pivotal role for glutamatergic neurotransmission in the pathophysiology ...
Background: Several reports have shown that the glutamatergic system is involved in both the pathoge...
During early stages of postnatal development, glutamate receptors of NMDA and AMPA type, undergo int...
WOS: 000330362600012PubMed: 23807397Objectives Glycogen synthase kinase 3 beta (GSK-3 beta) is recen...